KR102805250B1 - Mtorc1 조절제 및 이의 용도 - Google Patents

Mtorc1 조절제 및 이의 용도 Download PDF

Info

Publication number
KR102805250B1
KR102805250B1 KR1020227036354A KR20227036354A KR102805250B1 KR 102805250 B1 KR102805250 B1 KR 102805250B1 KR 1020227036354 A KR1020227036354 A KR 1020227036354A KR 20227036354 A KR20227036354 A KR 20227036354A KR 102805250 B1 KR102805250 B1 KR 102805250B1
Authority
KR
South Korea
Prior art keywords
delete delete
alkyl
optionally substituted
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227036354A
Other languages
English (en)
Korean (ko)
Other versions
KR20230084095A (ko
Inventor
존 킨케이드
Original Assignee
에오비안 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에오비안 파마슈티컬스, 인크. filed Critical 에오비안 파마슈티컬스, 인크.
Priority to KR1020257014654A priority Critical patent/KR102963519B1/ko
Publication of KR20230084095A publication Critical patent/KR20230084095A/ko
Application granted granted Critical
Publication of KR102805250B1 publication Critical patent/KR102805250B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Burglar Alarm Systems (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
KR1020227036354A 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도 Active KR102805250B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014654A KR102963519B1 (ko) 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063001177P 2020-03-27 2020-03-27
US202063001144P 2020-03-27 2020-03-27
US202063001187P 2020-03-27 2020-03-27
US63/001,177 2020-03-27
US63/001,144 2020-03-27
US63/001,187 2020-03-27
US202063019176P 2020-05-01 2020-05-01
US63/019,176 2020-05-01
US202063054762P 2020-07-21 2020-07-21
US202063054768P 2020-07-21 2020-07-21
US202063054763P 2020-07-21 2020-07-21
US63/054,762 2020-07-21
US63/054,768 2020-07-21
US63/054,763 2020-07-21
PCT/US2021/024536 WO2021195599A1 (en) 2020-03-27 2021-03-26 Mtorc1 modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014654A Division KR102963519B1 (ko) 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20230084095A KR20230084095A (ko) 2023-06-12
KR102805250B1 true KR102805250B1 (ko) 2025-05-08

Family

ID=77892684

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227036354A Active KR102805250B1 (ko) 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도
KR1020257014654A Active KR102963519B1 (ko) 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257014654A Active KR102963519B1 (ko) 2020-03-27 2021-03-26 Mtorc1 조절제 및 이의 용도

Country Status (11)

Country Link
US (3) US11634432B2 (enExample)
EP (1) EP4126229A4 (enExample)
JP (2) JP7606591B2 (enExample)
KR (2) KR102805250B1 (enExample)
CN (2) CN115776907B (enExample)
AU (2) AU2021241718B2 (enExample)
CA (1) CA3173722A1 (enExample)
IL (1) IL296828A (enExample)
MX (1) MX2022011964A (enExample)
WO (1) WO2021195599A1 (enExample)
ZA (1) ZA202210888B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) * 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
WO2024211738A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085400A1 (en) 2006-01-24 2007-08-02 Novartis Ag Process for the preparation of rapamycin derivatives
WO2019064182A1 (en) 2017-09-26 2019-04-04 Novartis Ag RAPAMYCIN DERIVATIVES

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
BR9408323A (pt) 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO1999036553A2 (en) * 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
IL147803A0 (en) * 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
EP1896075A2 (en) 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN103391780B (zh) * 2011-02-16 2015-08-19 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
WO2014153118A1 (en) * 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
US20190022073A1 (en) 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US10478561B2 (en) 2017-08-03 2019-11-19 Minhong Yu Wireless transmission system with integrated sensing capability
US10980784B2 (en) * 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
JP2024503898A (ja) 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085400A1 (en) 2006-01-24 2007-08-02 Novartis Ag Process for the preparation of rapamycin derivatives
WO2019064182A1 (en) 2017-09-26 2019-04-04 Novartis Ag RAPAMYCIN DERIVATIVES

Also Published As

Publication number Publication date
AU2021241718B2 (en) 2025-03-27
US11603377B2 (en) 2023-03-14
KR20250065937A (ko) 2025-05-13
WO2021195599A1 (en) 2021-09-30
JP7645431B2 (ja) 2025-03-13
CN119954829A (zh) 2025-05-09
MX2022011964A (es) 2022-12-02
KR20230084095A (ko) 2023-06-12
AU2025204768B2 (en) 2025-08-07
EP4126229A4 (en) 2024-04-17
KR102963519B1 (ko) 2026-05-11
AU2025204768C1 (en) 2026-02-05
IL296828A (en) 2022-11-01
US20220332727A1 (en) 2022-10-20
US11634432B2 (en) 2023-04-25
AU2025204768A1 (en) 2025-07-17
JP2025028197A (ja) 2025-02-28
BR112022019508A2 (pt) 2022-11-16
JP7606591B2 (ja) 2024-12-25
JP2023530778A (ja) 2023-07-19
US20220235069A1 (en) 2022-07-28
AU2021241718A1 (en) 2022-10-20
US20240002399A1 (en) 2024-01-04
ZA202210888B (en) 2024-02-28
CA3173722A1 (en) 2021-09-30
CN115776907A (zh) 2023-03-10
EP4126229A1 (en) 2023-02-08
CN115776907B (zh) 2025-02-25

Similar Documents

Publication Publication Date Title
KR102963519B1 (ko) Mtorc1 조절제 및 이의 용도
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
KR20220042431A (ko) 헤테로시클릭 rip1 키나제 억제제
AU2016322848B2 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
CA3120514A1 (en) Cyclic ureas
CN116322677B (zh) Mtorc1调节剂及其用途
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
CN106243088A (zh) 取代的哌嗪化合物及其使用方法和用途
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
TW202321244A (zh) 一種Ｗｎｔ通路抑制劑化合物
TW202304906A (zh) 高活性hpk1激酶抑制劑
BR112022019508B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR122024006050B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR122024006050A2 (pt) Moduladores de mtorc1 e seus usos
HK40096020A (en) Mtorc1 modulators and uses thereof
HK40096020B (zh) Mtorc1调节剂及其用途
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
WO2025185736A1 (zh) 一种多元螺环化合物的晶型、其制备方法和医药用途
WO2025185734A1 (zh) 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
KR20160098498A (ko) 피라졸 유도체 및 dlk의 억제제로서 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221019

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240325

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20240325

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240405

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250203

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250502

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250502

End annual number: 3

Start annual number: 1

PG1601 Publication of registration